YOLFTbeta
Shattuck Labs Inc

Shattuck Labs Inc

STTK · NASDAQ · Healthcare / Biotechnology

4.65USD-0.16 (-3.33%)

Price History

Full chart

Market Stats

Previous Close4.81
Open4.79
Day Range4.50 – 4.83
52-Week Range1.70 – 8.33
Volume775.90K
Market Cap609.20M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.44
Dividend Yield0.00%
Beta1.10
50-Day Avg6.97
200-Day Avg5.75

About

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Taylor H. Schreiber M.D., Ph.D.
  • Employees40
  • Headquarters500 West 5th Street, Austin, TX, United States, 78701, USA
  • Websitehttps://www.shattucklabs.com

Leadership

  • Dr. Taylor H. Schreiber M.D., Ph.D.Co-Founder, CEO & Director · b. 1980
  • Mr. Andrew R. Neill M.B.A.Chief Financial Officer · b. 1986
  • Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.Chief Medical Officer · b. 1959
  • Mr. Brad HuckabeeVice President of Accounting & SEC reporting
  • Dr. Abhinav A. Shukla Ph.D.Chief Technical Officer · b. 1973
  • Mr. Suresh de Silva Ph.D.Chief Scientific Officer
  • Dr. Stephen Stout J.D., Ph.D.General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer · b. 1975
  • Ms. Casi DeYoungChief Business Officer · b. 1971
  • Dr. Thomas Lampkin Pharm.D.Senior Vice President of Regulatory Affairs
  • Ms. Kelli Collin M.B.A., M.S.Senior Vice President of Quality

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue22.44M9.89M9.93M30.02M652.00K1.66M5.72M1.00M
Growth (%)--55.94%+0.48%+202.16%-97.83%+154.14%+245.26%-82.52%
Cost of Revenue24.81M29.22M37.48M1.38M3.38M4.04M4.89M2.95M
Gross Profit-2.37M-19.33M9.93M28.64M652.00K-2.38M827.00K-1.95M
Gross Margin-10.54%-195.52%100.00%95.40%100.00%-143.93%14.46%-195.10%
Operating Expense3.78M5.74M46.87M73.91M103.98M89.57M81.39M49.56M
Operating Income-6.15M-25.07M-36.93M-45.27M-103.33M-91.96M-80.57M-51.51M
Operating Margin-27.40%-253.53%-371.76%-150.81%-15848.01%-5549.61%-1408.27%-5150.80%
EBITDA-4.50M-24.53M-36.31M-43.59M-100.26M-83.26M-71.58M-45.12M
EBITDA Margin-20.06%-248.10%-365.54%-145.23%-15376.69%-5024.50%-1251.20%-4512.10%
Net Income-7.39M-23.98M-35.44M-44.97M-100.56M-87.30M-75.41M-48.81M
Net Income Margin-32.92%-242.56%-356.71%-149.83%-15423.47%-5268.44%-1318.13%-4880.90%
R&D24.81M29.22M37.48M56.56M82.90M74.31M67.21M35.27M
R&D as % of Total Revenue110.54%295.52%377.32%188.44%12714.57%4484.61%1174.81%3527.30%
Interest Expense2.63M001.38M3.07M---
Interest Expense % of Total Revenue11.72%0.00%0.00%4.60%471.32%---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets68.16M44.97M348.99M298.58M205.32M159.56M91.05M91.03M
Total Liabilities79.24M79.52M39.13M26.80M29.17M14.86M11.42M8.64M
Total Equity-11.08M-34.55M309.86M271.79M176.16M144.71M79.63M82.39M
Cash31.64M7.01M157.90M92.27M47.38M125.63M57.39M54.19M
Total Debt----4.90M4.20M3.41M2.42M
Net Debt-31.64M-7.01M-157.90M-92.27M-42.48M-121.42M-53.98M-51.77M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.90M-20.98M-33.66M-57.12M-94.50M-81.23M-60.52M-39.88M
Investing Cash Flow-29.93M-3.59M-146.32M-10.44M49.44M110.86M-8.51M-7.89M
Financing Cash Flow35.15M-64.00K330.87M1.93M171.00K48.62M787.00K44.57M
Capital Expenditure1.18M470.00K727.00K7.93M11.61M407.00K59.00K71.00K
Free Cash Flow-8.08M-21.45M-34.39M-65.04M-106.11M-81.64M-60.57M-39.95M
FCF to OCF117.07%102.24%102.16%113.88%112.29%100.50%100.10%100.18%

Earnings

Report DateSep 2, 2020Nov 13, 2020Mar 15, 2021May 10, 2021Aug 11, 2021Nov 9, 2021Mar 15, 2022May 12, 2022Aug 11, 2022Nov 8, 2022Feb 23, 2023May 9, 2023Aug 10, 2023Nov 9, 2023Feb 29, 2024May 2, 2024Aug 1, 2024Nov 14, 2024Mar 27, 2025Apr 30, 2025Aug 14, 2025Nov 6, 2025Mar 17, 2026May 7, 2026Aug 11, 2026Nov 5, 2026
EPS Estimate0.00-0.35-0.39-0.39-0.35-0.44-0.43-0.50-0.59-0.67-0.63-0.63-0.52-0.52-0.57-0.45-0.41-0.42-0.32-0.28-0.24-0.15-0.13-0.13-0.14-0.10
EPS Actual-0.36-1.54-0.31-0.28-0.56-0.410.18-0.58-0.65-0.58-0.60-0.49-0.50-0.65-0.41-0.37-0.42-0.33-0.37-0.27-0.24-0.14-0.12-0.13-0.12-
Surprise--340.00%20.51%28.21%-60.00%6.82%141.86%-16.00%-10.17%13.43%4.76%22.22%3.85%-25.00%28.07%17.78%-2.44%21.43%-15.63%4.42%0.00%6.67%8.81%0.00%14.29%-
Timing-Pre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hours-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap609.20M
Enterprise Value433.68M
Trailing P/E0.00
Forward P/E0.00
Price / Sales609.21
Price / Book3.03
EPS-0.44
Book Value2.10
Revenue (TTM)1.00M
Gross Profit (TTM)-38.24M
EBITDA-52.14M
Profit Margin0.00%
Operating Margin-5570.50%
Return on Equity-39.21%
Return on Assets-24.43%
Shares Outstanding100.36M
Shares Float67.76M
Beta1.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 14.67
  • Strong Buy
    2
  • Hold
    3

Ownership Breakdown

Institutions
80.14%
Insiders
4.08%
Retail / Other
15.78%

Top Institutional Holders

  • T. Rowe Price Investment Management,Inc.
    9.87M9.83%
  • Adage Capital Partners Gp LLC
    8.12M8.09%
  • Redmile Group, LLC
    6.89M6.87%
  • Orbimed Advisors LLC
    6.31M6.28%
  • Prosight Management, LP
    5.96M5.94%
  • NEXTBio Capital Management LP
    3.73M3.71%
  • Deep Track Capital, LP
    3.71M3.69%
  • Vanguard Capital Management, LLC
    2.28M2.27%
  • Pinnacle Associates Inc
    1.87M1.86%
  • T. Rowe Price Associates, Inc.
    1.78M1.78%
  • Wellington Management Company LLP
    1.77M1.76%
  • Clark Estates Inc
    1.43M1.43%
  • Aberdeen Group PLC
    1.41M1.40%
  • Point72 Asset Management, L.P.
    1.03M1.03%

Top Fund Holders

  • T. Rowe Price Small-Cap Value
    3.49M3.48%
  • T. Rowe Price Small-Cap Stock
    3.11M3.10%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.37M2.36%
  • T. Rowe Price Health Sciences
    2.35M2.34%
  • T. Rowe Price Instl Small-Cap Stock
    1.68M1.67%
  • iShares Russell 2000 ETF
    1.55M1.55%